What are you
looking for?


Siegfried’s Board of Directors and Executive Committee share the responsibility of steering the company towards our goals. Together, they uphold Siegfried’s values of excellence, passion, integrity, quality and sustainability, ensuring our continued success in a dynamic market.

Executive Comittee

Reto Suter

Chief Executive Officer ad interim and Chief Financial Officer

Reto Suter (1971) joined Siegfried on May 1, 2017, as Chief Financial Officer, additionally responsible for Cyber Security and Risk Management. On May 1, 2024, he took on the responsibilities as CEO ad interim until a permanent successor is found. Prior to joining Siegfried, he held a range of positions in industry as well as in finance and private equity. In his last function as COO, CIO and Board Member of Lonrho, a long-established company headquartered in London (UK) and Johannesburg (SA), Reto was responsible for overseeing the public takeover and subsequent delisting and restructuring. He is a member of the Board of Directors and Chairman of the Audit Committee of Inficon Holding AG.

Reto studied economics at the University of Zurich and the University of Washington in Seattle and completed his doctorate in banking and finance at the University of Zurich. He is a Swiss citizen.

Marcel Imwinkelried

Chief Operating Officer Drug Products

Marcel Imwinkelried (1967) joined the Siegfried Group in January 2021 as Multi-Site Head for the Drug Products sites in Barberà del Vallès and El Masnou (Spain) as well as Irvine (California) and was appointed Chief Operating Officer Drug Products effective October 2021. Previously, he was with Novartis since 2005 in various roles with increasing responsibility and, from 2018, was appointed Global Head Technical Operations Solids.

Marcel graduated in mechanical engineering from the Lucerne University of Applied Sciences and holds a degree in business administration from the University of St. Gallen. He is a Swiss citizen.

Henrik Krüpper

Chief Operating Officer Drug Substances

Henrik Krüpper (1971) joined the Siegfried Group as of September 2023 as the Chief Operating Officer Drug Substances. Prior to joining Siegfried, he was the CEO of HCS Group, an international speciality chemicals company based in Germany, starting in 2019. His other roles within HCS Group since joining in 2012 included Managing Director and Chief Commercial Officer. He started his career at Th. Goldschmidt AG as Site Excellence and Production Manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH.

Henrik holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen in Germany. Henrik is a German citizen.

Jürgen Roos

Chief Scientific Officer

Jürgen Roos (1968) joined the Siegfried Group in April 2019 as Chief Scientific Officer. Before joining Siegfried, Jürgen worked for Evonik Industries AG as Vice President for Innovation Management of the Animal Nutrition business line. Jürgen started his professional career at Evonik (formerly Degussa-Hüls and Degussa AG) in 1999 as Laboratory Team Leader in chemical research in the field of fine chemicals. After various functions within the R&D organization of Evonik, including several years in Canada and the United Kingdom, he was appointed Head of Process Development in the field of exclusive synthesis in 2008, and subsequently took over the global responsibility for research and development of Evonik’s Health Care division. Jürgen is on the Board of Directors of the European Fine Chemicals Group (EFCG), the industry association of European fine chemical manufacturers, where he chairs the Innovation Committee.

Jürgen studied chemistry at the University of Stuttgart and obtained a Ph.D. in organic chemistry. He is a German citizen.

Marianne Späne

Chief Business Officer Drug Substances and Drug Products

Marianne Späne (1962) joined the Siegfried Group in 2004 and was appointed Chief Business Officer in March 2010. She headed the Siegfried Generics Division from 2008 to 2010. From 2004 to 2008, Marianne managed the Business Development Department and the supply chain for generics. Prior to joining Siegfried, Marianne held various positions with Aceto, a US-based pharmaceutical company, where she developed European expansion strategies, and held the role of Head of the Sales and Marketing of the pharma division of Schweizerhalle. Before joining the pharmaceutical industry, she worked in logistics, business development and as site manager for Boucheron, a cosmetics company.

Marianne holds degrees in finance, business administration and marketing from the Business Management School (KFS) in Basel and the Marketing & Business School in Zurich (MBSZ). She is a German citizen.

Irene Wosgien

Chief Human Resources Officer

Irene Wosgien (1973) joined the Siegfried Group in 2019 and was appointed to the Executive Committee as Chief Operating Officer Drug Substances in 2021. As of July 2023, she assumed the function of Chief Human Resources Officer of the Siegfried Group.  She has many years of experience in custom manufacturing in the pharmaceutical and food industry. Before joining Siegfried, Irene spent 20 years with the DSM group, holding various senior management positions, most recently as Vice President Operations Human Nutrition & Health. She worked and lived in the Netherlands, Austria and Switzerland.

Irene holds a Master’s degree in chemical engineering from Eindhoven University and a Master’s degree in Management
of Safety, Health and Environment from the University of Delft. She is a Dutch citizen.

Board of Directors

Andreas Casutt


Andreas Casutt (1963) joined the Board of Siegfried Holding AG in 2010 and was elected Chairman in 2014. He has been a partner at the law firm Niederer Kraft Frey AG in Zurich since 2002, for which he also serves on the board of directors and held office as managing partner from 2006 to 2014. Andreas specializes in corporate law, contract law, mergers & acquisitions, and stock exchange law. He is a board member of the publicly traded Mikron Holding AG and maxon international AG (as well as its sister company maxon motor AG). In addition, he is a board member of Dextra Rechtsschutz AG, Format A AG, Vanco Switzerland AG and holds various board mandates for the investment company Horizon21 AG and its related companies (SO Holding AG, Roymar Corporation SA, Lakeside Services AG, Lakeside Aviation AG, Sole Invest AG, Allwinden Holding AG) as well as privately owned ImmSell AG and ImmOthmar AG. Furthermore, Andreas Casutt chairs the board of TPIO Holding AG, its subsidiary Belleview AG and OPG Online Personals Group AG and he is a managing director of privately owned
HEROS Helvetic Rolling Stock GmbH and its subsidiary HEROS America Middel-East Asia GmbH.

Andreas studied law and received his Ph.D. at the University of Zurich and completed an LL.M. program at the University of Michigan, Ann Arbor. He is a Swiss citizen.

Martin Schmid

Vice Chairman

Martin Schmid (1969) has been a member of Siegfried Holding AG’s Board of Directors since 2016 and was elected Vice-Chairman in 2020. He is an attorney-at-law, co-founder and partner in the law firm Kunz Schmid, Chur. In 2011, he was elected State Councillor of the Canton of Graubünden. From 2003 to 2011, he was a member of the Canton of Graubünden government, where he headed the Department of Justice, Security and Health and subsequently the Department of Finance. He is a member of the board of directors of Swiss
Life AG and Swiss Life Holding AG, is chariman of the board of EKW AG and ELIN AG and a board member of Swissgas AG. He also chairs the board of Calanda Holding AG (and of its subsidiaries Calanda Gruppe AG and Gribag AG), as well as chairs the Swiss Gas Industry Association (VSG ASIG), the Swiss Development Association, the Graubünden Cantonal Hospital Foundation and the Institute of Finance and Financial Law at the University of St. Gallen (IFF-HSG). In addition, he is a member of the board of economiesuisse, the umbrella organization of the Swiss economy, and of the advisory counsel of ExpertSuisse.

Martin studied law at the University of St. Gallen, where he received his doctorate in 2005. He is a Swiss citizen.

Alexandra Brand

Board Member

Alexandra Brand (1971) joined the Board of Siegfried Holding AG in 2022 and is a member of Siegfried’s Strategy & Sustainability Committee. She is a member of the Global Leadership Team of the Syngenta Group, in the position of Executive Vice President, Sustainability and Corporate Affairs since November 2023. Prior to that, Alexandra Brand led one of Syngenta Group’s largest businesses units as the Crop Protection Regional Director for EAME. From 2018–2020, she was Chief Sustainability Officer of Syngenta Group where she led the newly created Business Sustainability Group to evolve existing sustainability initiatives and to drive forward the company’s sustainability agenda. Alexandra Brand originally joined Syngenta in late 2015 as Regional Director of Syngenta’s crop protection and seed operations across Europe, Africa and the Middle East. Prior to joining Syngenta, Alexandra held various positions with increasing importance and responsibility with BASF for more than 15 years. She is a member of the board of directors of Azelis, a public listed leading global distributor of specialty chemicals and food ingredients.

Alexandra studied Chemistry at the University of Darmstadt, where she also received her Ph.D. in inorganic chemistry in 1998. She is a German citizen.

Wolfram Carius

Board Member

Wolfram Carius (1961) joined the Board of Siegfried Holding AG in 2014 and chairs Siegfried’s Strategy & Sustainability Committee and is a member of the Audit Committee. He is a member of the Executive Leadership Team of Bayer Pharma since 2020, in the position of Executive Vice President Pharmaceuticals, with responsibility for the new created Cell and Gene therapy. Prior, he served as Executive Vice President Pharmaceuticals Product Supply at Bayer and member of the Executive Committee at Bayer Pharma. From 2013-2016, Wolfram worked for Sanofi, a French healthcare company, as Senior Vice President Biopharma Biologics and member of the Global Leadership Team. From 1987 to 2013, he held various positions with the pharma company Boehringer Ingelheim. In 2009, he was appointed to the company’s Board of Managing Directors, initially with responsibility for HR and Technical Operations, and from 2012 for Biopharma and Operations. Before that, he was responsible for the development and expansion of the biopharma unit. He managed the company’s production site in Japan and worked later in Brazil as technical director before being appointed member of Boehringer Ingelheim’s Board of Managing Directors in Germany. serves on the boards of Südpack Medica AG, Switzerland, and FinVector Oy, Finland, a company of Ferring Ventures, Switzerland. In addition, he is Co-founder and member of the Advisory Board of Artistratis GmbH, Germany.

Wolfram holds a Ph.D. in Pharmaceutical Biology and Analytical Phytochemistry from the University of Saarland, Germany. In 2009, the Biberach University of Applied Sciences awarded him the title of honorary professor in recognition of his long and exceptional service. He is a German citizen.

Elodie Carr-Cingari

Board Member

Elodie Carr-Cingari (1974) was elected to the Board of Siegfried Holding AG in 2023 and chairs Siegfried’s Audit Committee. She has been the Chief Financial Officer of the Landis+Gyr Group since 2020. Previously, she held the position of Chief Financial Officer of the Hoerbiger Group. Prior to that, Elodie spent 11 years with Alstom and later, following the Alstom acquisition, General Electric, where she held several CFO positions of global businesses in the Energy and Grid sectors. She spent the first 10 years of her career with Hewlett-Packard where she held different finance leadership roles.

Elodie holds a Master of Business Administration from Bocconi University in Milan. She is a French and Swiss citizen.

Beat Walti

Board Member

Beat Walti (1968) joined the Board of Siegfried Holding AG in 2022 and is a member of Siegfried’s Remuneration Committee as well as the Strategy & Sustainability Committee. He is and attorney-at-law, partner and members of the board of directors of Wenger Vieli, a Zurich-based law firm since 2007, specializing in commercial and corporate law and governance issues. From 1999 to 2013, Beat was a member of the Cantonal Council of Zürich. In 2014, he became a member of the Swiss National Council, where he sits on the Economic Affairs and Taxation Committee and also presided over the parliamentary group of “FDP/the liberals” from 2017 – 2022. Beatchairs the Foundation Board of the Ernst Göhner Foundation and the board of directors of Rahn AG. He is a member of the board of directors of DSV A/S in Denmark and of EGS Beteiligungen AG and a member of the advisory board of PricewaterhouseCoopers AG and Pure Holding AG. In addition, Beat Walti is chairman of the boards of OSPITA (Association of Swiss Enterprises in the Healthcare Sector) and of VIS (Association of institutional real estate investors in Switzerland), member of the advisory counsel of ExpertSuisse as well as of other private foundations and associations.

Beat studied law at the Universities of Neuchâtel and Zurich and received his Ph.D. in 1998. He is a Swiss citizen.

Isabelle Welton

Board Member

Isabelle Welton (1963) was elected to the Board of Siegfried Holding AG in 2020 and chairs Siegfried’s Renumeration Committee. She is the owner of a consulting firm specializing in corporate culture and change processes, which she founded in 2018. From 2013 to 2017, she was as member of the Group Executive Board of the Zurich Insurance Group with responsibility for Human Resources & Corporate Culture. Isabelle started her career with Citibank in Tokyo and subsequently changed to IBM, where she held various positions in marketing and communications before being appointed country general manager of IBM in Switzerland. Isabelle serves as the chairwoman of the board of directors of AG für die Neue Zürcher Zeitung and is a member of the board of the Avobis Group and the Swiss Institute of International Studies as well as the foundation boards of Swisscontact, SOS Children’s Village Switzerland and the Lucerne Festival.

Isabelle holds a degree in law from the University of Zurich and has furthered her education at various universities in Australia and the USA. She is a Swiss citizen.

Board committees

In order to strengthen the corporate governance of Siegfried, three committees support and advise the Board of Directors in the following areas: Audit, Remuneration and Strategy & Sustainability. The committees typically consist of three Board members with relevant experience in the committee’s field of responsibilities. Download the Organizational Regulations for more details on our committees.

Audit Committee

The Audit Committee supports the Board of Directors in overseeing Siegfried’s financial integrity, internal controls, external audit, internal auditing, and financial risk management. Elodie Carr-Cingari is the Chairwoman and Dr. Martin Schmid and Dr. Wolfram Carius are members of the committee.

Remuneration Committee

The Remuneration Committee advises the Board of Directors on compensation and other people-related matters, including remuneration strategy, policies and reports. Isabelle Welton is the Chairwoman and Dr. Martin Schmid and Dr. Beat Walti are members of the committee.

Strategy and Sustainability Committee

The Strategy and Sustainability Committee supports the Board of Directors in shaping Siegfried’s long-term strategic direction, corporate strategy, and sustainability efforts, including environmental, social, and governance matters. Dr. Wolfram Carius is the Chairman and Dr. Alexandra Brand and Dr. Beat Walti are members of the committee.

Board statements

Board independence statement

In accordance with the Siegfried Group Board Regulations, the Chairman of the Board of Directors, the Chairman of the Audit Committee as well as the majority of the members of the Board of Directors must be non-executive and independent. In line with the Swiss Code of Best Practice, the members of the Board of Directors are considered non-executive and independent if they (i) are currently not members of the Executive Committee and have not belonged to the Executive Committee in the last three years, and (ii) have no or only relatively minor business relations with Siegfried.

Board diversity statement

The Board of Directors embraces the “Diversity, Inclusion and Equality Policy of the Siegfried Group“. For the composition of its Board of Directors, Siegfried aims to achieve and maintain an appropriate balance of skills and knowledge, taking into account the core and adjacent business fields of the pharmaceutical industry in which Siegfried is active, its international orientation, the accounting and legal requirements of listed companies, as well as the growing need for Board level expertise in the fields of compensation, digitalization and sustainability. A diverse Board with different views improves decision-making and ensures sustainable decision-making and long-term success in the interest of all our stakeholders.

Hence, the Board of Directors considers and values a variety of individual criteria of its members, including industry experience, experience in executive and management functions, knowledge in finance and accounting, governance, compliance and law, expertise in ESG and information technology, as well as gender and other diversity criteria. In accordance with the Diversity, Inclusion and Equality Policy of the Siegfried Group, Siegfried strives to achieve a gender diversity with women representing no less than 30% of its Board members.

The Board regularly conducts a self-assessment of the performance of its members as well as its processes and organization, with the target to improve the governance, enhance efficacy, identify gaps in the skill sets and diversity and define future priorities.

Current Board composition

The Board of Directors of Siegfried Holding AG currently consists of seven non-executive members from four different countries. Three of the seven members of the Board of Directors are female (quota of 43%). All members of the Board of Directors of the current term of office qualify as non-executive and independent within the meaning of the Swiss Code of Best Practice for Corporate Governance. None of the current members ever held a position in the Executive Committee of Siegfried or any other company of the Siegfried Group, nor did they, or the companies or organizations they represent, ever have any significant business relationship with Siegfried.

To top